Galapagos NV (AMS:GLPG)
28.74
-0.82 (-2.77%)
Oct 14, 2025, 5:35 PM CET
Galapagos NV Revenue
Galapagos NV had revenue of 65.29M EUR in the quarter ending June 30, 2025, a decrease of -16.16%. This brings the company's revenue in the last twelve months to 275.61M, up 5.43% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
275.61M
Revenue Growth
+5.43%
P/S Ratio
6.87
Revenue / Employee
493.92K
Employees
704
Market Cap
1.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGalapagos NV News
- 13 days ago - Galapagos Receives Non-Binding Offers For Cell Therapy Business - Nasdaq
- 13 days ago - Galapagos (GLPG) Explores Strategic Alternatives for Cell Therapy Division - GuruFocus
- 13 days ago - Galapagos (GLPG) Considers Strategic Options for Cell Therapy Unit - GuruFocus
- 13 days ago - Galapagos updates on strategic alternatives for cell therapy business - Seeking Alpha
- 13 days ago - Biotechnology firm Galapagos receives offers for cell-therapy business - Reuters
- 13 days ago - Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business - GlobeNewsWire
- 2 months ago - Galapagos Creates New Subscription Right Plan - GlobeNewsWire
- 2 months ago - Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma - GlobeNewsWire